Effectiveness of pembrolizumab in therapy of sarcomatoid variant of metastatic urothelial carcinoma. Clinical case
https://doi.org/10.17650/1726-9776-2024-20-4-104-111
Abstract
Sarcomatoid variant of urothelial carcinoma is a rare histological subtype: it is diagnosed in 0.1–0.3 % of all neoplasms of the bladder. The standard 1st line therapy for all types of advanced urothelial carcinoma is chemotherapy which does not necessarily allow to achieve the best or complete responses, especially in the presence of sarcomatoid differentiation. High programmed cell death-ligand 1 (PD-L1) expression in this morphological subtype allows to assume better results of immunotherapy compared to chemotherapy. However, a large number of observations is necessary to confirm this hypothesis and suggest pembrolizumab immunotherapy as a standard 1st line therapy for metastatic urothelial carcinoma with sarcomatoid differentiation.
About the Authors
A. S. Polyakova
S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center, Moscow Healthcare Department
Russian Federation
Competing Interests:
Russian Federation
Aleksandra S. Polyakova.
5 2nd Botkinskiy Proezd, Moscow 125284
Competing Interests:
None
E. A. Sokolov
S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center, Moscow Healthcare Department; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
5 2nd Botkinskiy Proezd, Moscow 125284; Build. 1, 2/1 Barrikadnaya St., Moscow 125993
Competing Interests:
None
D. Yu. Pushkar
S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center, Moscow Healthcare Department; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia; Russian University of Medicine, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
5 2nd Botkinskiy Proezd, Moscow 125284; Build. 1, 2/1 Barrikadnaya St., Moscow 125993; 4 Dolgorukovskaya St., Moscow 127006
Competing Interests:
None
References
1. Lenis A.T., Lec P.M., Chamie K., Mshs M.D. Bladder cancer: a review. JAMA 2020;324(19):1980–91. DOI: 10.1001/jama.2020.17598
2. Gu L., Ai Q., Cheng Q. et al. Sarcomatoid variant urothelial carcinoma of the bladder: a systematic review and metaanalysis of the clinicopathological features and survival outcomes. Cancer Cell Int 2020;20(1):550. DOI: 10.1186/s12935020016269
3. Sui W., Matulay J.T., Onyeji I.C. et al. Contemporary treatment patterns and outcomes of sarcomatoid bladder cancer. World J Urol 2017;35(7):1055–61. DOI: 10.1007/s0034501619628
4. Konala V.M., Adapa S., Aronow W.S. Immunotherapy in bladder cancer. Am J Ther 2022;29(3):e334–7. DOI: 10.1097/MJT.0000000000000934
5. Evans S.T., Jani Y., Jansen C.S. et al. Understanding and overcoming resistance to immunotherapy in genitourinary cancers. Cancer Biol Ther 2024;25(1):2342599. DOI: 10.1080/15384047.2024.2342599
6. Bellmunt J., de Wit R., Vaughn D.J. et al. Pembrolizumab as second line line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376(11):1015–26. DOI: 10.1056/NEJMoa1613683
7. Miller N.J., Khaki A.R., Diamantopoulos L.N. et al. Histological subtypes and response to PD1/PDL1 blockade in advanced urothelial cancer: a retrospective Study. J Urol 2020;204(1):63–70. DOI: 10.1097/JU.0000000000000761
8. Kobayashi T., Ito K., Kojima T. et al.; Japan Urological Oncology Group. Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab. Cancer Sci 2021;112(2):760–73. DOI: 10.1111/cas.14762
9. Iacovelli R., Ciccarese C., Bria E. et al. Patients with sarcomatoid renal cell carcinoma – redefining the firstline of treatment: a metaanalysis of randomised clinical trials with immune checkpoint inhibitors. Eur J Cancer 2020;136:195–203. DOI: 10.1016/j.ejca.2020.06.008
10. Kotlowska M.P., Rueda A.G., Olmedo M.E. et al. Efficacy of immunotherapy in sarcomatoid lung cancer, a case report and literature review. Respir Med Case Rep 2019;26:310–4. DOI: 10.1016/j.rmcr.2019.02.017
11. Tsurumi K., Kawashima Y., Akahira J. et al. A remarkable clinical response to pembrolizumab in a rare spindle cell carcinoma of the lung. JMA J 2020;3(1):83–6. DOI: 10.31662/jmaj.20190015
12. Jin C., Yang B. Dramatic response of pulmonary sarcomatoid carcinoma to nivolumab combined with anlotinib: a case report. Case Rep Oncol 2020;13(2):601–5. DOI: 10.1159/000507568
13. Li H., Zhang Q., Shuman L. et al. Evaluation of PDL1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes. Sci Rep 2020;10(1):1439. DOI: 10.1038/s41598020583516
14. Murase K., Nakane K., Kawase M. et al. Metastatic urothelial carcinoma with sarcomatoid subtype after robotassisted radical cystectomy successfully treated with pembrolizumab. Cureus 2024;16(6):e61871. DOI: 10.7759/cureus.61871
Review
For citations:
Polyakova A.S., Sokolov E.A., Pushkar D.Yu. Effectiveness of pembrolizumab in therapy of sarcomatoid variant of metastatic urothelial carcinoma. Clinical case. Cancer Urology. 2024;20(4):104-111. (In Russ.) https://doi.org/10.17650/1726-9776-2024-20-4-104-111
Views:
155
Email this article 